EPICS Therapeutics

EPICS Therapeutics pioneers therapies targeting RNA epigenetic regulation, focusing on the epitranscriptome where enzymes write, read, and erase marks on RNA to control gene expression. The company's lead program EP102 is a potent and selective small-molecule inhibitor of METTL3 that is now in clinical evaluation in patients with solid tumors.